Patterns of transmitted HIV drug resistance in Europe vary by risk group.

Patterns of transmitted HIV drug resistance in Europe vary by risk group.

<h4>Background</h4>In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.<h4>Methods</h4>HIV-1...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dineke Frentz, David van de Vijver, Ana Abecasis, Jan Albert, Osamah Hamouda, Louise Jørgensen, Claudia Kücherer, Daniel Struck, Jean-Claude Schmit, Jurgen Vercauteren, Birgitta Asjö, Claudia Balotta, Colm Bergin, Danail Beshkov, Ricardo Camacho, Bonaventura Clotet, Algirdas Griskevicius, Zehava Grossman, Andrzej Horban, Tatjana Kolupajeva, Klaus Korn, Leondios Kostrikis, Kirsi Liitsola Marek Linka, Claus Nielsen, Dan Otelea, Dimitrios Paraskevis, Roger Paredes, Mario Poljak, Elisabeth Puchhammer-Stöckl, Anders Sönnerborg, Danica Stanekova, Maja Stanojevic, Anne-Mieke Vandamme, Charles Boucher, Annemarie Wensing, SPREAD Programme
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2014
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/cb11271513de4669a456b9fb91457921
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:<h4>Background</h4>In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported.<h4>Methods</h4>HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression.<h4>Results</h4>From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non- nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively).<h4>Conclusions</h4>MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.

Ejemplares similares